Acumen Pharmaceuticals (ABOS)
(Delayed Data from NSDQ)
$2.50 USD
-0.08 (-3.10%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $2.51 +0.01 (0.40%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Cash flow Statements
Fiscal Year End for Acumen Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -52.37 | -42.86 | -100.61 | -7.33 | -7.91 |
Depreciation/Amortization & Depletion | -2.94 | 0.66 | 0.16 | 0.00 | 0.00 |
Net Change from Assets/Liabilities | 3.87 | 3.99 | 0.30 | 0.31 | 0.77 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 8.38 | 3.06 | 82.19 | -0.43 | 0.32 |
Net Cash From Operating Activities | -43.06 | -35.15 | -17.96 | -7.45 | -6.82 |
Property & Equipment | -0.02 | -0.16 | -0.04 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -171.65 | 39.35 | -104.08 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -171.67 | 39.19 | -104.12 | 0.00 | 0.00 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 122.23 | 3.91 | 200.47 | 44.68 | 6.23 |
Issuance (Repayment) of Debt | 30.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
Other Financing Activities | -0.48 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 151.75 | 3.91 | 200.47 | 44.68 | 6.24 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -62.98 | 7.94 | 78.39 | 37.23 | -0.58 |
Cash at Beginning of Period | 130.10 | 122.16 | 43.78 | 6.55 | 7.13 |
Cash at End of Period | 67.12 | 130.10 | 122.16 | 43.78 | 6.55 |
Diluted Net EPS | -1.08 | -1.06 | -5.02 | -17.48 | NA |
Fiscal Year End for Acumen Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -35.41 | -14.87 | -52.37 | -35.87 | -22.92 |
Depreciation/Amortization & Depletion | -3.13 | -1.72 | -2.94 | -1.20 | -0.53 |
Net Change from Assets/Liabilities | -0.30 | -4.07 | 3.87 | -2.19 | -1.31 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 4.44 | 2.80 | 8.38 | 4.51 | 2.91 |
Net Cash From Operating Activities | -34.40 | -17.86 | -43.06 | -34.75 | -21.85 |
Property & Equipment | -0.02 | -0.01 | -0.02 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 28.51 | -9.19 | -171.65 | -122.86 | -30.86 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 28.50 | -9.20 | -171.67 | -122.86 | -30.86 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 7.91 | 7.91 | 122.23 | 122.62 | 0.00 |
Issuance (Repayment) of Debt | -0.74 | -0.74 | 30.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.19 | -0.06 | -0.48 | 0.00 | -0.15 |
Net Cash from Financing Activities | 6.98 | 7.11 | 151.75 | 122.62 | -0.15 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 1.07 | -19.96 | -62.98 | -35.00 | -52.85 |
Cash at Beginning of Period | 67.12 | 67.12 | 130.10 | 130.10 | 130.10 |
Cash at End of Period | 68.19 | 47.16 | 67.12 | 95.11 | 77.25 |
Diluted Net EPS | -0.34 | -0.25 | -0.28 | -0.24 | -0.28 |